Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Proceeds From Payments For Sale Of Huntsville Manufacturing Facility Net

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%
Enterprise value$2.27B+874%
P/S39.4×+37.8×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept nktr:ProceedsFromPaymentsForSaleOfHuntsvilleManufacturingFacilityNet.

The official record: Nektar Therapeutics’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's proceeds from payments for sale of huntsville manufacturing facility net.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's proceeds from payments for sale of huntsville manufacturing facility net?
Nektar Therapeutics (NKTR) reported proceeds from payments for sale of huntsville manufacturing facility net of -$174.25K in Q4 2025.
How has Nektar Therapeutics's proceeds from payments for sale of huntsville manufacturing facility net changed year-over-year?
Nektar Therapeutics's proceeds from payments for sale of huntsville manufacturing facility net decreased by 101.1% year-over-year, from $16.35M to -$174.25K.